GAS41 polyclonal Antibody | BS8517

GAS41 polyclonal Antibody | BS8517 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB,IHC

Application Range: WB 1:2000 - 1:5000 IHC 1:50 - 1:200

Background: Gene amplification is associated with tumor stage and progression in human gliomas. Several amplified loci are identified and comprise multiple genes. The glioma amplified sequence 41 (GAS41) is an evolutionarily conserved eukaryotic protein found in diverse species. GAS41 is related to the AF-9 and ENL proteins, which are putative transcription factors in some acute leukemias,and interacts with a component of the nuclear matrix, NuMA, in interphase cells. GAS41 has a dotted staining pattern in interphase nuclei and a uniform distribution in mitotic cells. GAS41 is ubiquitously expressed, with the highest levels of expression in human brain. In neuroblastoma, GAS41 is located in the nucleoli, but not in the nucleoplasm. GAS41 also binds to the MLL fusion partner AF-10, which is involved in two distinct chromosomal translocations associated with hematologic malignancy. In addition, GAS41 interacts with INI1 (integrase interactor 1), which is a human homolog of the yeast Snf5 protein, a component of the SWI/SNF complex. The GAS41 gene maps to human chromosome 12q13-q15.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: GAS41 polyclonal Antibody detects endogenous levels of GAS41 protein.

Molecular Weight: ~ 26kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: YEATS domain-containing protein 4; Glioma-amplified sequence 41; Gas41; NuMA-binding protein 1; NuBI-1; NuBI1; YEATS4; GAS41

Immunogen: Recombinant full length Human GAS41.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: